Details of the Drug Combination

General Information of Drug Combination (ID: DCX1A9W)

• Drug Combination Name: Mitapivat + IT-141
• Indication: Diffuse intrinsic pontine glioma; Status: Investigative [1]
• Component Drugs:
  Mitapivat (DMXI8X0): N.A.
  IT-141 (DMAYD7O): N.A.
• High-throughput Screening Result:
  Testing Cell Line: DIPG25
  Zero Interaction Potency (ZIP) Score: 6.871
  Bliss Independence Score: 16.701
  Loewe Additivity Score: 4.435
  LHighest Single Agent (HSA) Score: 4.335

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Mitapivat

Disease Entry	ICD 11	Status	REF
Hereditary haemolytic anemia	3A10.3	Approved	[2]
Pyruvate kinase deficiency	5C53.00	Phase 2	[3]

Mitapivat Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Pyruvate kinase PKLR (PKLR)	TT31N4S	KPYR_HUMAN	Activator	[2]

Indication(s) of IT-141

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]

IT-141 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
DNA topoisomerase I (TOP1)	TTGTQHC	TOP1_HUMAN	Inhibitor	[4]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 216196.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)